Shares of Bluebird Bio Inc. (NASDAQ:BLUE) fell 0.4% during mid-day trading on Friday . The stock traded as low as $47.50 and last traded at $48.62, with a volume of 533,584 shares. The stock had previously closed at $48.83.

Several research firms have recently issued reports on BLUE. Vetr downgraded Bluebird Bio from a “strong-buy” rating to a “buy” rating and set a $55.90 price target for the company. in a research note on Wednesday, April 6th. Goldman Sachs Group Inc. restated a “buy” rating and set a $149.00 target price on shares of Bluebird Bio in a research note on Monday, April 11th. Jefferies Group restated a “buy” rating and set a $80.00 target price on shares of Bluebird Bio in a research note on Friday. Cantor Fitzgerald began coverage on Bluebird Bio in a research note on Thursday, June 2nd. They set a “hold” rating and a $42.00 target price for the company. Finally, BTIG Research restated a “buy” rating and set a $72.00 target price on shares of Bluebird Bio in a research note on Wednesday, April 20th. One research analyst has rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $96.09.

The firm’s market capitalization is $1.80 billion. The firm’s 50 day moving average price is $43.33 and its 200-day moving average price is $46.59.

Bluebird Bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, May 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by $0.29. During the same quarter in the previous year, the business posted ($0.76) earnings per share. The business earned $1.50 million during the quarter, compared to analysts’ expectations of $4.50 million. The firm’s revenue was down 76.2% on a year-over-year basis. Equities analysts anticipate that Bluebird Bio Inc. will post ($5.90) earnings per share for the current fiscal year.

In other Bluebird Bio news, insider David Davidson sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, April 15th. The stock was sold at an average price of $49.63, for a total transaction of $49,630.00. Following the transaction, the insider now owns 10,600 shares of the company’s stock, valued at $526,078. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Philip D. Gregory sold 2,931 shares of the business’s stock in a transaction that occurred on Thursday, June 16th. The stock was sold at an average price of $39.52, for a total value of $115,833.12. Following the transaction, the insider now directly owns 30,069 shares in the company, valued at approximately $1,188,326.88. The disclosure for this sale can be found here.

Other large investors have recently modified their holdings of the company. Jennison Associates LLC boosted its stake in shares of Bluebird Bio by 171.3% in the fourth quarter. Jennison Associates LLC now owns 864,314 shares of the company’s stock worth $55,506,000 after buying an additional 545,727 shares in the last quarter. Columbus Circle Investors boosted its stake in shares of Bluebird Bio by 170.2% in the fourth quarter. Columbus Circle Investors now owns 315,957 shares of the company’s stock worth $20,291,000 after buying an additional 199,014 shares in the last quarter. OppenheimerFunds Inc. boosted its stake in shares of Bluebird Bio by 16.7% in the fourth quarter. OppenheimerFunds Inc. now owns 1,316,324 shares of the company’s stock worth $84,534,000 after buying an additional 188,840 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Bluebird Bio by 53.4% in the fourth quarter. Wells Fargo & Company MN now owns 474,832 shares of the company’s stock worth $30,492,000 after buying an additional 165,303 shares in the last quarter. Finally, Marshall Wace LLP boosted its stake in shares of Bluebird Bio by 374.8% in the fourth quarter. Marshall Wace LLP now owns 168,427 shares of the company’s stock worth $10,816,000 after buying an additional 132,956 shares in the last quarter.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.